ORAL CONTRACEPTIVES AND FOLLICLE STIMULATING HORMONE

ORAL CONTRACEPTIVES AND FOLLICLE STIMULATING HORMONE

924 TETRACYCLINE BLOOD-LEVELS (IN g. PER ml. I.S.E.M.) IN mg. 8 HEALTHY q.i.d. AND drawn, while the other 4 ate breakfast. Serum-tetracyclin...

116KB Sizes 0 Downloads 2 Views

924 TETRACYCLINE BLOOD-LEVELS

(IN g.

PER

ml. I.S.E.M.)

IN

mg.

8

HEALTHY

q.i.d.

AND

drawn, while the other 4 ate breakfast. Serum-tetracycline activity was determined by the agar-diffusion method with Bacillus cereus var. mycoides (ATCC 9634), using tetracycline was

U.S.P. as the standard. As shown in the accompanying table, adequate levels are obtained with 300 mg. of lymecycline b.d.; in addition there is the advantage of higher peaks of serum-antibiotic activity, after each administration, which are not greatly affected by meals. L. VITARTALI Ospedale Civile di Merate, A. PISANI-CERETTI. Como, Italy.

SUBJECTS AFTER 300 mg. b.d.

mone

from

ORAL ADMINISTRATION OF

(L.H.) was measured by laboratory.2

a

method

LYMECYCLINE, 150

previously reported

our

F.S.H. and L.H. were measured on daily samples in six women, who were admitted to hospital for the study, in control cycles and cycles during which they received norethynodrel 2-5 mg. and mestranol 01mg. daily for 17-25 days beginning on the 2nd day of flow. In a typical normal menstrual cycle plasmaF.S.H. was significantly raised in the first half of the follicular phase, followed by a sharp midcycle peak of lesser magnitude than the L.H. peak; F.S.H. luteal-phase levels were significantly less than follicular levels (fig. 1). Similar results were seen in 21 normal menstrual cycles in the women. F.S.H. values in the control cycle of a second woman and in response to the oral

ORAL CONTRACEPTIVES AND FOLLICLE STIMULATING HORMONE our knowledge, the effects of oral contraceptives plasma-follicle-stimulating-hormone (F.S.H.) levels in women have not been reported, though Stevens et a1.l reported

SiR,ņTo

on

decreased F.S.H. excretion in the urine after ethynodiol diacetate and mestranol. We report here the effects of an oral contraceptive on plasma-levels of F.s.H. measured by a double-antibody method of radioimmunoassay, using ’Reichert 780 ’ pituitary F.S.H. labelled with 131J and rabbit antihuman F.S.H. serum, with the International Reference Preparation, no. 2, of human menopausal gonadotrophin as reference standard. Luteinising hor1. Stevens, V. 14, 327.

C., Vorys, N., Besch, P. K., Barry, R. D. Metabolism, 1965,

Fig. 2-Plasma-F.S.H. in a second woman during a control cycle (on left), and in response to norethynodrel 25 mg. and mestranol 01 mg. daily, beginning on 2nd day of flow (on right).

contraceptive are shown in fig. 2. The early follicular rise and the midcycle peak were obliterated, and all values were comparable to the luteal-phase levels of the control cycle. The same response was seen in all six women receiving the contraceptive. The suppression of plasma-F.s.H. by norethynodrel and mestranol was similar to the previously reported suppression of plasma L.H.3 in the

same women.

Endocrinology Branch, National Cancer Institute, Bethesda, Maryland 20014.

C. M. CARGILLE G. T. Ross.

PROJECTIONS IN EOSINOPHILS SIR,-Nuclear projections (nuclear pockets or blebs) similar NUCLEAR

those described by Epstein and Achong4 have been found in several types of normal and abnormal cells of the blood, lymph-nodes, bone-marrow, and thymus, and in lymphoid, neutrophilic, and monocytic leucocytes-e.g., in thymocytes and Reed-Sternberg cells. It has been suggested that these nuclear features are a physiological structure in all forms of leucocytes,5and they have been described in immature bonemarrow granulocytes from patients on fluorouracil 6 or cytarabine hydrochlorideand from those with untreated pernicious anaemia,6 in peripheral-blood myeloblasts of treated

to

2. Odell, W. D., Ross, G. T., Rayford, P. L. ibid. 1966, 15, 287. 3. Ross, G. T., Odell, W. D., Rayford, P. L. Lancet, 1966, ii, 1255. 4. Epstein, M. A., Achong, B. G. J. natn. Cancer Inst. 1965, 34, 241. 5. Huhn, D. Nature, Lond. 1967, 216, 1240. 6. Stalzer, R. C., Kiely, J. M., Pease, C. L., Brown, A. L., Jr. Cancer,

Fig. 1—F.S.H. (solid line) and L.H. (interrupted line) in plasmasamples taken daily during a normal menstrual cycle in a representative woman.

7.

N.Y., 1965, 18, 1071. Ahearn, M. J., Lewis, C. W., Campbell, L. A. Nature, Lond. 1967, 215, 196.